IRulya Therapeutics Inc.
IRLA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001662774
No open-market purchases or sales by IRulya Therapeutics Inc. insiders were filed in the last 90 days; 32 institutions reported holding it in 13F filings for Q3 2026, worth $66.8M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 18, 2026
- $440.1M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ3 2026, +6 vs. previous quarter
- 32
- 13F valueReported value at the end of Q3 2026
- $66.8M
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$84.0M
- No comparable prior period
- Free cash flow, FY2025
- -$41.8M
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 127.8K
- Shares sold short
- Change
- −26.9K
- −17.4% vs. previous
- Days to cover
- 1.13
- At average daily volume
Superinvestors holding IRLA, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding IRLA at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by IRulya Therapeutics Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 29, 2025 (view filing) | Dec 26 | 3 days | Benatti LucaDirector | SSale | −50.0K | $3.47 | −$173.5K | −56.1%39.2K after | |
| Sep 3, 2024 (view filing) | Aug 29-30 | 5 days | Thye DirkCEO AND CHIEF MEDICAL OFFICER | PPurchase | +154.5K | $0.695 | +$107.4K | +22.4%843.9K after | 2 lots |
| Aug 22, 2024 (view filing) | Aug 20 | 2 days | Ryan Charles S.PRESIDENT | PPurchase | +48.4K | $0.65 | +$31.5K | +65.3%122.5K after | |
| Aug 21, 2024 (view filing) | Aug 19-21 | 2 days | Hannah BrendanCHIEF BUSINESS OFFICER AND COO | PPurchase | +38.9K | $0.6209 | +$24.2K | +15.1%296.5K after | 6 lots |
| Dec 14, 2023 (view filing) | Dec 12-14 | 2 days | Lamond DavidDirector | PPurchase | +45.6K | $1.02 | +$46.5K | +2.0%2.35M after | 3 lots |
| Dec 14, 2023 (view filing) | Dec 12 | 2 days | Lamond DavidDirector | PPurchase | +22.3K | $1.02 | +$22.8K | +1.0%2.30M after | |
| Dec 7, 2023 (view filing) | Dec 5-7 | 2 days | Lamond DavidDirector | PPurchase | +57.4K | $1.01 | +$58.1K | +2.6%2.28M after | 3 lots |
| Dec 1, 2023 (view filing) | Nov 29-Dec 1 | 2 days | Lamond DavidDirector | PPurchase | +43.1K | $0.94 | +$40.5K | +2.0%2.22M after | 3 lots |
| Aug 31, 2023 (view filing) | Aug 30-31 | 1 day | Lamond DavidDirector | PPurchase | +82.1K | $1.32 | +$107.9K | +3.9%2.18M after | 2 lots |
| Aug 17, 2023 (view filing) | Aug 15-17 | 2 days | Lamond DavidDirector | PPurchase | +250.0K | $1.30 | +$325.7K | +13.5%2.10M after | 3 lots |
Top 10 13F holders, Q3 2026
See all 32 holdersThe largest institutional positions in IRulya Therapeutics Inc. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Janus Henderson Group PLC | 1,714,957 | $53.2M | 0.02% | +1,714,957 | New |
| Ikarian Capital, LLC | 95,652 | $2.97M | 0.59% | +23,401+32.4% | Added |
| Squadron Capital Management LLC | 90,000 | $2.79M | 0.83% | +49,625+122.9% | Added |
| Millennium Management LLC | 72,254 | $2.24M | 0.00% | +1,475+2.1% | Added |
| Acuta Capital Partners, LLC | 52,918 | $1.64M | 1.27% | +52,918 | New |
| Birchview Capital, LP | 40,601 | $1.26M | 0.73% | +40,601 | New |
| Boothbay Fund Management, LLC | 21,291 | $660.2K | 0.01% | +7,380+53.1% | Added |
| Jane Street Group, LLC | 20,156 | $625.0K | 0.00% | +7,514+59.4% | Added |
| Seven Fleet Capital Management LP | 11,989 | $371.8K | 0.07% | +11,989 | New |
| Geode Capital Management, LLC | 9,741 | $302.1K | 0.00% | +9,741 | New |
Holders of 5% or more of IRLA
See all 8 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of IRulya Therapeutics Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Group One Trading, L.P. | 13G | 10.70%5.94M shares | New | Mar 5, 20261 filing | Mar 5, 2026 | SEC |
| Cormorant Asset Management, LP | 13G | 9.99%108.0K shares | New | Aug 14, 20261 filing | Aug 14, 2026 | SEC |
| Balyasny Asset Management LLC | 13G/A | 9.99%101.6K shares | 0.00 ppfrom 9.99% | Aug 14, 20262 filings | Nov 16, 2026 | SEC |
| Squadron Capital Management LLC | 13G/A | 8.80%90.0K shares | +3.20 ppfrom 5.60% | Aug 4, 20262 filings | Nov 16, 2026 | SEC |
| Perceptive Advisors LLC | 13G | 8.40%912.9K shares | New | Oct 14, 20261 filing | Oct 14, 2026 | SEC |